Log In
BCIQ
Print this Print this
 

Oradur-methylphenidate (Oradure-ADHD)

  Manage Alerts
Collapse Summary General Information
Company Durect Corp.
DescriptionOnce-daily metyhlphenidate formulated using Oradur sustained release technology
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationAttention deficit hyperactivity disorder (ADHD)
Indication DetailsTreat attention deficit hyperactivity disorder (ADHD)
Regulatory Designation
PartnerOrient Europharma Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today